Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: improved revenue and EPS guidance, stable demand environment, and cost-saving measures are positive. However, uncertainties in divestitures, DSA growth, and reliance on nascent NAMs technologies add caution. The Q&A section highlighted analyst concerns about divestitures and growth forecasts. Despite raised guidance, the lack of clear growth predictions and divestiture specifics tempers optimism, leading to a neutral sentiment.
Key Financial Performance
Revenue $1 billion in the third quarter of 2025, a 0.5% decrease year-over-year. On an organic basis, revenue declined 1.6% due to declines in both the DSA and Manufacturing segments, partially offset by an increase in the RMS segment. The decline was attributed to tighter budgets from small and midsized biotech clients and the loss of a large commercial client in the CDMO business.
Operating Margin 19.7% in the quarter, a decrease of 20 basis points year-over-year. The decline was driven by lower sales volume in the DSA segment and lower commercial CDMO revenue in the Manufacturing segment.
Earnings Per Share (EPS) $2.43 in the third quarter, a 6.2% decline from the third quarter of last year. The decline was primarily due to a significant year-over-year tax rate increase, totaling $0.24 per share, due to new tax legislation.
DSA Segment Revenue $600.7 million in the third quarter, a 3.1% year-over-year decrease on an organic basis. The decline was driven by lower revenue for both Discovery and Safety Assessment Services, partially offset by a modest benefit from favorable study mix.
RMS Segment Revenue $213.5 million, an increase of 6.5% on an organic basis compared to the third quarter of 2024. The growth was driven by the favorable timing of NHP shipments.
Manufacturing Segment Revenue $190.7 million, a 5.1% decrease on an organic basis from the third quarter of last year. The decline was largely driven by lower commercial revenue from CDMO clients.
Free Cash Flow $178.2 million in the third quarter, compared to $213.1 million in the same period last year, representing a decrease primarily driven by lower earnings.
CapEx $35.6 million or approximately 3.5% of revenue in the third quarter, compared to $38.7 million last year, reflecting a focus on disciplined capital spending.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NAMs (New Approach Methodologies): Focus on advancing NAMs capabilities, including next-generation sequencing solutions, recombinant bacterial endotoxin tests, and in vitro immunogenicity assessments. These efforts aim to reduce reliance on animal models and enhance drug development efficiency.
Geographic Presence: Evaluating opportunities to enhance geographic presence as part of growth initiatives.
Cost Savings Initiatives: Implemented restructuring initiatives expected to save $225 million annually by 2026, representing a 5% cost reduction. Additional process improvements and procurement synergies to save $70 million annually by 2026.
Operational Efficiency: Adopting a global business services model and enhancing client relationships through technology platforms and clinical data access.
Portfolio Refinement: Plan to divest underperforming or non-core businesses, representing 7% of 2025 revenue, to focus on profitable growth opportunities. Expected to result in $0.30 per share earnings accretion annually post-divestiture.
Capital Allocation: Board approved a $1 billion stock repurchase authorization, replacing the previous authorization. Focus on balancing acquisitions, stock repurchases, and debt repayment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Uncertainty in end markets and cautious client demand, particularly from small and midsized biotech clients, due to tighter budgets and a softer biotech funding environment.
Competitive Pressures: Loss of a large commercial client in the CDMO business, impacting revenue and creating a $20 million revenue headwind in the second half of the year.
Regulatory Hurdles: Biologics Testing business facing lower sample volumes due to project delays or regulatory challenges for several large clients.
Supply Chain Disruptions: Higher third-party NHP sourcing costs due to procurement of additional models to support better-than-expected demand.
Economic Uncertainties: Impact of new tax legislation (OB3 Act) and global minimum tax provisions, increasing the non-GAAP tax rate by 700 basis points year-over-year.
Strategic Execution Risks: Challenges in divesting underperforming or non-core businesses, which represent 7% of estimated 2025 revenue, and ensuring timely completion by mid-2026.
Operational Efficiency: Pressure on operating margins in DSA and Manufacturing segments due to lower sales volume and higher staffing costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: For 2025, organic revenue is expected to decline by 1.5% to 2.5%, with reported revenue declining by 0.5% to 1.5%. Fourth-quarter revenue is projected to range from flat to a low single-digit decline year-over-year.
Earnings Per Share (EPS) Guidance: Non-GAAP EPS for 2025 is expected to be in the range of $10.10 to $10.30, reflecting a $0.10 increase from the midpoint of the prior guidance range. Fourth-quarter EPS is expected to be flat to 10% below the third-quarter level of $2.43.
Operating Margin Outlook: The full-year operating margin is expected to be flat to a 30 basis point decline. Fourth-quarter margins will face pressure in the DSA segment due to higher staffing and NHP sourcing costs, and in the RMS segment due to timing of NHP shipments and seasonal trends.
Capital Expenditures and Free Cash Flow: CapEx for 2025 is projected to be approximately $200 million, representing about 5% of revenue. Free cash flow is expected to range from $470 million to $500 million, an increase from the prior outlook of $430 million to $470 million.
DSA Segment Outlook: DSA revenue for 2025 is expected to decline by 2.5% to 3.5% on an organic basis. Fourth-quarter DSA revenue is projected to be stable to modestly below the third-quarter level.
RMS Segment Outlook: RMS revenue for 2025 is expected to be flat to slightly positive on an organic basis. Fourth-quarter RMS revenue will be lower due to the acceleration of NHP shipments into the third quarter and normal seasonal trends.
Manufacturing Segment Outlook: Manufacturing revenue for 2025 is expected to be flat to slightly lower on an organic basis. Fourth-quarter revenue is expected to improve due to year-end ordering patterns in the Microbial Solutions business.
Biotech and Biopharma Demand Trends: Biotech funding and proposal activity improved in the third quarter, with cautious optimism for continued improvement in demand over the coming quarters. Biopharma demand is expected to rebound, supported by improved funding and proposal activity.
Strategic Divestitures: The company plans to divest underperforming or non-core businesses, representing approximately 7% of estimated 2025 revenue. These divestitures are expected to be completed by mid-2026 and result in non-GAAP earnings accretion of at least $0.30 per share annually.
Cost Savings Initiatives: Restructuring initiatives are expected to result in $225 million in cumulative annualized cost savings by 2026, with an additional $70 million in annual savings from process improvements and operating efficiencies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Authorization: The Board of Directors approved a new $1 billion stock repurchase authorization, replacing the previous authorization. Since August 2024, $450.7 million in common stock had been repurchased under the previous authorization. The company will evaluate the level of stock repurchases considering valuation, growth prospects, expected returns, earnings accretion, leverage, and other cash uses.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about what you're seeing from customers in terms of demand trends and the biotech market?
A:James Foster mentioned that proposals are up with both large pharma and biotech clients, cancellation levels are declining, and net bookings are up for pharmaceutical clients. Biotech funding was significantly high in Q3, with October being the second-highest month in biotech history. He noted that biotech funding constraints over the past 18 months have impacted expenditures, but the market seems to have bottomed out. There is an increase in early pre-IND work and general Tox studies, indicating strengthening demand.
Q:Is there a path to DSA growing in '26, and what does that mean for margins?
A:James Foster stated that they need to see the conclusion of the year, the beginning of next year, and the finalization of client budgets for '26. Improvement in book-to-bill over a sustained period, backlog movement, and the nature of studies (short-term vs. long-term) will influence growth. They are hopeful for improvement but will monitor closely.
Q:Are you seeing more short-term studies, and how does that impact revenue and backlog?
A:James Foster confirmed they are seeing more short-term or pre-IND work, which is a positive sign of client comfort in spending. The backlog is around 9 months, which is optimal for flexibility and quicker revenue generation. This trend indicates incremental spending, particularly by biotech clients.
Q:Are you experiencing any issues with study start timing, as some competitors have reported?
A:James Foster stated that they are able to start studies relatively quickly and align with client timeframes. They have a shorter backlog with studies starting more rapidly, which aligns well with client needs.
Q:Can you provide details on the targeted divestitures and their impact?
A:James Foster avoided specifics but mentioned that the divestitures represent around 7% of revenue and should generate $0.30 accretion annually. They are important to the divestiture process but declined to specify the assets.
Q:Are you seeing any changes in client behavior regarding NAMs (New Approach Methodologies)?
A:James Foster noted that while there is recognition of NAMs, most technologies are nascent and provide early-stage information. Clients are not significantly shifting to NAMs yet, as alternatives are not scientifically robust. Charles River is investing in NAMs technologies and aims to be a leader in this area.
Q:Can you elaborate on the additional $70 million in cost savings and their impact?
A:Michael Knell explained that the savings come from facility consolidation, workforce rightsizing, procurement savings, GBS scalability, and internal efficiencies. These savings will offset inflationary pressures and protect operating income. About $100 million of incremental savings is expected in 2026, but not all will drop to the bottom line.
Q:How much of the $100 million in cost savings for '26 will fall to the bottom line?
A:Michael Knell stated that it is too early to determine how much will fall to the bottom line, but the focus is on reinvigorating earnings growth.
Q:What is the outlook for DSA growth in '26, given recent book-to-bill trends?
A:James Foster highlighted improving trends such as increased proposals, reduced cancellations, and better net bookings. However, he refrained from predicting '26 growth, emphasizing the need for continued positive trends and client budget finalizations.
Q:What are your thoughts on the BIOSECURE Act and its impact?
A:James Foster mentioned that they have not seen any impact from the BIOSECURE Act and hear little about it from clients.
Q:Were proposals healthy in Q3, and how did DSA bookings progress during the quarter?
A:James Foster noted that proposals for mid-tier clients were up year-over-year and sequentially, while global client proposals were up year-over-year but flat sequentially. Cancellations were down, and net bookings improved for global clients. He did not provide specific monthly book-to-bill figures but mentioned improving trends.
Q:What is the timing of asset divestitures, and how will they be treated in financial reporting?
A:James Foster stated that they aim to complete divestitures by mid-year but are not at the LOI stage yet. Michael Knell added that the assets will remain in continuing operations until divested, as they do not qualify for discontinued operations.
Q:How long does it take for improved biotech funding to show up in backlog and revenue?
A:James Foster explained that there is usually a lag of a couple of quarters as biotech clients cautiously spend. However, pent-up demand and a desire to file INDs could accelerate this timeline.
Q:What is the current capacity utilization in DSA, and how does it impact growth?
A:James Foster mentioned that capacity utilization is below the optimal low-80s range but allows for incremental capacity to accommodate growth. They are building incremental space in laboratory sciences to meet demand.
Q:What is the impact of increased staffing in DSA on future growth?
A:James Foster stated that incremental hiring is essential to meet demand and backfill positions. Staffing levels are being adjusted to accommodate expected growth in 2026.
Q:What is the appetite for inorganic growth and leverage levels for strategic acquisitions?
A:James Foster emphasized a focus on strategic acquisitions in core areas like bioanalysis, geographic expansion, and NAMs technologies. They are comfortable with leverage in the mid-to-high 2s, with a commitment to keep it under 3 turns.
Q:Is pricing in DSA stable, and how does it impact competition?
A:James Foster stated that spot pricing is stable, and selective discounting is used strategically to protect or gain market share. Pricing is expected to improve as demand increases and space tightens.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the targeted divestitures, including the assets involved. They also refrained from quantifying month-over-month book-to-bill figures and the exact amount of cost savings that will fall to the bottom line in 2026. Additionally, they did not provide a clear prediction for DSA growth in '26, citing the need for further data and client budget finalizations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CDMO
Chief
DSA segment
Interim
Manufacturing segment
NAMs
NHP shipment
Officer
RMS
action
activity client
approach
basis point
booking
capability
capital
cash
debt
decline
decrease
demand
digit
drug
efficiency
end
improvement
increase
interest
level
margin
model
outlook
portfolio
rate
repurchase authorization
review
stock repurchase
testing
value
CRL Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Neutral6-2
Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary reveals solid financial performance, optimistic guidance, and strategic initiatives that indicate potential growth. The Q&A section highlights positive trends such as increased proposal volumes, AI's potential in drug discovery, and improving margins. Although there are some uncertainties, like the sluggish demand from smaller biotechs, the overall sentiment is positive due to strong financial metrics, optimistic guidance, and strategic focus on M&A and capital allocation. Despite the lack of market cap data, these factors suggest a likely positive stock price movement in the short term.
Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
CRL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
